Trial Profile

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HS-10502 Combination Treatment in Subjects with Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 30 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Docetaxel (Primary) ; HS 10502 (Primary) ; HS-20089 (Primary) ; HS-20093 (Primary) ; Irinotecan (Primary) ; Paclitaxel (Primary) ; Platinum complexes (Primary) ; Rivoceranib (Primary)
Indications Advanced breast cancer; Gastric cancer; HER2 negative breast cancer; Ovarian cancer; Prostate cancer; Solid tumours
Focus Adverse reactions; Therapeutic Use
Sponsors Jiangsu Hansoh Pharmaceutical

Most Recent Events

05 Jun 2025 Addition of 1 cohort in treatment .
05 Jun 2025 Planned number of patients changed from 154 to 157.
05 Jun 2025 Planned End Date changed from 30 Sep 2026 to 31 Aug 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com